Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 2

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT...

Colorado’s Ibogaine Bill Could Be a Landmark — If It Respects the Plant’s Roots

Joe Moore Psychedelics Today on Leadership, Integration, and the Psychedelic Landscape

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

Pα+ February 2026 Psychedelic Bill Roundup

Q1 2026 Psychedelic Drug Development Pipeline: Bullseye Charts

Couples Are Turning to Ketamine-Assisted Therapy to Heal Their Relationships

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude...

Q4’25 Psychedelic Lobbying Update

Ketamine Assisted Psychotherapy for Couples

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human...

Dr. Chandra Khalifian and Dr. Kayla Knopp: Enamory, Psychedelics, and Couples...

Taking the Helm at Helus: A Brief Q&A With New CEO...

The Psychedelic Practitioner Issue 3: Dosing

Load more

EDITOR PICKS

Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley...

Colorado’s Ibogaine Bill Could Be a Landmark — If It Respects...

Joe Moore Psychedelics Today on Leadership, Integration, and the Psychedelic Landscape

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©